[바이오클론] [Biorbyt 한국독점대리점]Recombinant Antibodies
분류 : 시약 > Antibody
전화 : 02-2690-0058
메일 : bioclone(at).bioclone.co.kr
팩스 : 02-2690-0397
카탈로그 NO
제품 생산일
원산지
생산기업

 

www.biorbyt.com

www.bioclone.co.kr/biorbyt 

 

바이오클론은 영국 Biorbyt한국 독점 대리점

으로 합리적인 가격으로 제공하고 있습니다.

 

** Product Type **

Antibodies  Small Molecules

ELISA Kits Biology Tools

Proteins  Services


** Research Area **

Neuroscience Cacer Cardiavascular

바이오클론㈜는 Biorbyt의 한국독점대리점이며, 2015년부터 정부의 화학물질 등록 및 평가 등에 관한 법률(화평법)에 의해 모든 화학물질을 한국환경공단에 신고, 허가하에 안전하게 수입, 공급하고 있습니다.

 

 

 

Biorbyt

 

 

 

Recombinant Antibodies

 

 

 

Recombinant Antibodies: Reliable reagents for your research

 

 

 

 

The increasing use of antibodies in research dictates the need for more consistency and reliability. Recombinant antibodies are produced by cloning antibody genes into expression vectors.

 

Recombinant Antibodies: Reliable reagents for your Research

 

Recombinant Antibodies Background

The increasing use of antibodies in research dictates the need for more consistency and reliability. Recombinant antibodies are produced by cloning antibody genes into expression vectors. These vectors are then introduced into non-animal hosts, allowing the in vitro production of identical antibodies that can be mass-produced. Furthermore, the immunogen sequence is known at the outset of production and antibodies to unusual targets such as toxins or unique protein modifications can more easily be generated. Recombinant antibodies, due to the use of expression vectors do not suffer the same genetic drift as traditional monoclonal antibodies, ensuring consistency and quality between batches. Biorbyt’s range of recombinant monoclonal antibodies allows us to provide a constant, dependable supply of tailored antibodies specific to your target of interest, allowing you to focus on your research goals without interruption.

Recombinant Antibodies Production

There are two main methods for generating Recombinant Antibodies, in vivo and in vitro.

In vitro Recombinant Antibody Production Cycle

During in vitro production, synthetic gene sequences are cloned into vectors and introduced into hosts such as yeast or bacteria. These vectors subsequently reproduce, generating recombinant monoclonal antibodies. This process has numerous advantages:

  • Faster than in vivo, usually taking just a few weeks.

  • Can produce higher quantities of antibodies without causing harm to the host.

  • Able to produce antibodies that are traditionally difficult to generate via in vivo methods.

In vivo Recombinant Antibody Production Cycle

Using the in vivo hybridoma technique, antibodies are generated in a similar way to traditional antibodies, as recombinant antibodies are cloned from hybridized B-cells. This is achieved by immunising a host with the antigen, followed by isolating the B-cells that are produced. The antibody sequence generated by the B-cell is cloned and expressed, followed by thorough testing and screening for the highest specificity and binding. The heavy and light immunoglobulin chain genes are subsequently cloned into expression vectors, ready to produce identical recombinant antibodies.

We have a growing library of validated recombinant antibodies. Contact us for advice to support your research.

Advantages and Applications of Recombinant Antibodies

  • Ensures consistent quality between antibodies and batches.

  • Tailored specificity and increased efficacy.

  • Continuous production ensures a fast and reliable supply without compromising on quality.

  • DNA is available and stable for production and long term storage.

Recombinant antibodies are suitable in any situation that you would use monoclonal antibodies. Research areas and applications using recombinant antibodies include:

  • Flow cytometry.

  • Drug therapy.

  • Western Blot.

  • Immunohistochemistry.

  • Immunoprecipitation.

  • Immunofluorescence.

  • Structural biology.

  • Immunotherapy.

Several types of recombinant antibody fragment are now recognised and utilised for different applications:

  • Fv, variable fragment. This is the smallest antibody fragment retaining antigen binding capacity. Consisting of variable fragments of light (VL) and heavy (VH) chains they tend not to be very stable fragments.

  • scFv, single chain Fv, where heavy and light chain fragments are connected. These fragments have been developed as possible drug candidates, as well as components or domains of drug candidates. They are the “simplest” target for cloning and expression but can be unstable during therapeutic use. They have a shorter half-life in circulation compared to larger fragments.

  • (scFv)2, fragment - 2 connected scFv molecules. These have better in vivo transport into tissues compared with the scFv-fragments.

  • dsFv, variable fragment. These are often expressed in bacterial and yeast expression systems when they’re small non-glycosylated antibody fragments.

  • Fab- and (Fab)2, fragments - synthetically expressed versions of the familiar fragments generated by enzyme digestion of classically raised immunoglobulins.

  • VH, heavy chain variable domain. Single-chain fragment variable (scfv) molecules combining the coding sequence of the variable heavy (VH) and sequence of the variable light chain (VL) domains in a single-gene encoded format.

  • Diabodies, triabodies and tetrabodies. These molecules consist of two, three, or four identical or different fragments of antibodies of the same or different specificity linked together.

Poor quality antibodies contribute to a considerable amount of wasted research funds. Antibodies that lack specificity and function produce results that are not reliable or reproducible. Recombinant antibodies overcome these issues, saving both time and money.

 

 

 
 

New Product Launch!

 

We're excited to announce an important addition to our infectious disease product range, to help with furthering your Coronavirus research:

Human SARS-CoV-2 trimeric soluble full-length Spike protein

 
 

Human SARS-CoV-2 trimeric soluble full-length Spike protein

   

Catalogue Number: orb668935

Reactivity: Human

Application: WB

Sequence: 16-1213

 
 

Find out more

 
 

 

 
 
 

Biorbyt Antibody Conjugates

 

 

   
 
 

Antibody conjugates

 

We offer primary antibodies conjugated to a range of fluorescent and enzymatic labels.

 
 

Explore our conjugates

 
 

 

 
 

Our mission is to help with your research

 
 

 

 
 

www.biorbyt.com

 
 

FacebookLinkedInTwitter

 
 

Email: info@biorbyt.com

Phone: +44 (0)1223 859 353

Fax:+44 (0)1223 280 240

 
 

© 2020 Biorbyt Ltd. All Rights Reserved.

5 Orwell Furlong, Cowley Road, Cambridge. CB4 0WY.

 

 small sizeBulk size의 공급이 가능, 자세한 문의사항은 바이오클론으로 문의해 주시기 바랍니다.
궁금한 사항은 바이오클론으로 문의해 주세요.

upload image

 

 

 

주소복사
HOME   |   이용약관   |   개인정보처리방침
© BRIC